Umezawa, Yoshihiro
Sasaki, Koji http://orcid.org/0000-0002-9140-0610
Article History
Received: 28 June 2022
Revised: 26 July 2022
Accepted: 26 July 2022
First Online: 10 September 2022
Declarations
:
: YU declares no conflict of interest. KS received honoraria from Otsuka and research funding from Novartis and served on advisory boards of Pfizer Japan, Novartis, and Takeda.